Xenon Pharmaceuticals Inc.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $311.0K
- Net income
- -$345.9M
- Total assets
- $633.2M
- Market cap
- $5.0B
- Operating margin
- -4974.3%
- Net margin
- -4612.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $7.5M
- Operating expenses
- $380.6M
- Operating income
- -$373.1M
- Income tax
- $1.0M
- Net income
- -$345.9M
- EPS (basic)
- $-4.36
- EPS (diluted)
- $-4.36
Balance sheet
- Total assets
- $633.2M
- Current assets
- $560.6M
- Total liabilities
- $51.4M
- Current liabilities
- $41.8M
- Shareholders’ equity
- $581.8M
Cash flow
- Operating cash flow
- -$279.1M
- Investing cash flow
- $218.0M
- Financing cash flow
- $117.1M
- Net cash flow
- $56.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.0B
- EPS (diluted)
- $-4.36
- Shares outstanding
- 97.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 5, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $345.9M in FY2017.
- Revenue declined 77% from FY2020 to FY2025.
- Trading 18% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Xenon Pharmaceuticals Inc..
Write a review
News about Xenon Pharmaceuticals Inc.
News & sentiment via Polygon.io
